Dear dupa,

We're doing something new with Post-Hoc Live next week.

Our May 7 episode — a Q1 earnings recap with Endpoints News — will be exclusive to Insider and Enterprise subscribers as a benefit of their all-access premium subscription. If you’d like to tune in, I invite you to upgrade your subscription. And, you will get unlimited access to all our content. 

After a deal-heavy first quarter, earnings season is in full swing. I'll be joined by our reporters and analysts to break down what we're hearing from biopharma about their outlook for the rest of 2026 — whether more deals are coming, how MFN pricing is playing out and where things stand in the oral weight-loss race between Novo and Lilly.

Add it to your calendar here.

Hope you'll join us,

Drew Armstrong
Executive Editor
Endpoints News